The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus

Ann Rheum Dis. 1999 Mar;58(3):193-5. doi: 10.1136/ard.58.3.193.

Abstract

Objectives: Factors contributing to the development of systemic lupus erythematosus (SLE) remain largely unknown although are likely to include both environmental and genetic components. Studies on murine lupus have indicated a role for an antibody that blocks binding of cytotoxic T lymphocyte associated-4 (CTLA-4) to B7 on antigen presenting cells in the treatment of disease, suggesting that CTLA-4 may play an important part in the disease process. This study, therefore, investigated the frequency of a previously described A-G polymorphism in exon 1 of the CTLA-4 gene, the G allele of which has shown to be associated with both Graves' disease and type I diabetes, to determine whether this polymorphism was playing a part in the development of SLE.

Methods: One hundred and twenty six SLE patients and 363 control subjects were genotyped for the A-G polymorphism in exon 1 of the CTLA-4 gene. Target DNA was amplified using the polymerase chain reaction and the resulting product was digested using the BbvI restriction enzyme.

Results: No differences in allele or genotype frequencies were observed between patients with SLE and control subjects.

Conclusion: These data suggest that the A-G polymorphism in exon 1 of the CTLA-4 gene does not play a part in the genetic susceptibility to the development of SLE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept
  • Alleles
  • Antigens, CD
  • Antigens, Differentiation / genetics*
  • CTLA-4 Antigen
  • Case-Control Studies
  • Chi-Square Distribution
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Immunoconjugates*
  • Lupus Erythematosus, Systemic / genetics*
  • Polymorphism, Genetic*

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immunoconjugates
  • Abatacept